The ligand paradox between affinity and efficacy: Can you be there and not make a difference?

Trends in Pharmacological Sciences

Volumn 23, Issue 6, 2002, Pages 275-280

  Kenakin, Terry ^a   Onaran, Ongun ^b  

^a GLAXOSMITHKLINE   (United States)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; IMIDAZOLE; LIGAND; CELL SURFACE RECEPTOR;

BINDING AFFINITY; BIOCHEMISTRY; CONFORMATION; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; STIMULATION; STRUCTURE ACTIVITY RELATION; CHEMICAL MODEL; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION;

LIGANDS; MODELS, CHEMICAL; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, CELL SURFACE;

EID: 0036591660     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02036-9     Document Type: Review

References (63)

1. A personal view of pharmacology
2. Histamine H2-receptor agonists and antagonists
3. Receptor interactions of imidazolines. I. Affinity and efficacy for alpha adrenergic receptors in rat aorta
4. Aromatic and benzylic hydroxyl substitution of imidazle olines and phenethylamines: Differences in activity at alpha-1 and alpha-2 adrenergic receptors
5. Relative contributions of affinity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency
6. Hydrogen exchange and the dynamic structure of proteins
7. Is the slow-exchange core the protein folding core?
8. Primary structure effects on peptide group hydrogen exchange
9. Protein folding intermediates: Native-state hydrogen exchange
10. Determinants of protein hydrogen exchange studied in equine cytochrome c
11. Experimental study of the protein folding landscape: Unfolding reactions in cytochrome c
12. Structural mechanisms for domain movements in proteins
13. Forces and factors that contribute to the stuctural stability of membrane proteins
14. Essential dynamics of protein
15. Predicting the equilibrium protein folding pathway: Structure-based analysis of staphylococcal nuclease
16. Structure-based statistical thermodynamic analysis of T4 lysozyme mutants: Structural mapping of cooperative interactions
17. The structural distribution of cooperative interactions in proteins: Analysis of the native state ensemble
18. Predicting the equilibrium protein folding pathway: Structure-based analysis of staphylococcal nuclease
19. Model systems for the study of seven-transmembrane-segment receptors
20. Structure and function of G protein-coupled receptors
21. Specificity of receptor G protein interactions: Searching for the structure behind the signal
22. Three cytoplasmic loops of rhodopsin interact with transducin
23. Multisite contacts involved in coupling of the β-adrenergic receptor with the stimulatory guanine-nucleotide-binding regulatory protein
24. Affinity and intrinsic activity in the theory of competitive inhibition. Part I. Problems and theory
25. A modification of receptor theory
26. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxy terminus
27. Endocytosis and recycling of G-protein-coupled receptors
28. Regulatory mechanisms that modulate signaling by G-protein-coupled receptors
29. μ opioid receptor phosphorylation, desensitization, and ligand efficacy
30. Beta adrenergic kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with the ability to promote receptor phosphorylation
31. Modeling activation and desensitization of G-protein coupled receptors provides insight into ligand efficacy
32. Agonist-induced phosphorylation of the angiotensin II (AT1A) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state
33. 5]enkephalin- mu-opioid complexes demonstrated by cyclic independent protein kinase phosphorylation
34. Differential opioid agonist regulation of the mouse μ opioid receptor
35. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor
36. Potential inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
37. HIV co-receptor down-regulation as an antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication
38. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
39. Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: Implications for chemotaxis
40. Morphine activates opioid receptors without causing their rapid internalization
41. Agonist-receptor efficacy II: Agonist trafficking of receptor signals
42. Inverse, protean, and ligand-selective agonism: Matters of receptor conformation
43. Agonist efficacy and allosteric models of receptor action
44. A look at receptor efficacy. From the signaling network of the cell to the intramolecular motion of the receptor
45. Efficacy at G-protein coupled receptors
46. Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins
47. 1b -adrenergic subtypes
48. Fluorescent labeling of purified β2-adrenergic receptor: Evidence for ligand specific conformational changes
49. Inverse agonism of histamine H-2 antagonists accounts for up-regulation of spontaneously active histamine H-2 receptors
50. Inverse agonism and the regulation of receptor number
51. 2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells
52. 1B-adrenoceptor
53. 2C receptor systems
54. Treatment with inverse agonists enhances baseline atrial contractility in transgenic mice with chronic β2-adrenoceptor activation
55. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors
56. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
57. Chemokine receptors-the new frontier for aids research
58. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?
59. Chemokine receptor utilization by hiuman immunodeficiency virus type 1 isolates that replicate in microglia
60. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC CCR-5
61. A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
62. 3H-cimetidine in brain